Literature DB >> 30948866

Prevention and Treatment of Peritoneal Metastases: a Comprehensive Review.

Paul H Sugarbaker1.   

Abstract

Peritoneal metastases may occur from a majority of cancers that occur within the abdomen or pelvis. When cancer spread to the peritoneal surfaces is documented, a decision regarding palliation versus an aggressive approach using cytoreductive surgery (CRS) and hyperthermic perioperative intraperitoneal chemotherapy (HIPEC) must be made. This decision is dependent on a well-defined group of prognostic indicators. In addition to treatment, prevention of peritoneal metastases may be an option. The clinical and pathologic features of a primary cancer can be used to select perioperative treatments that may prevent cancer cells within the abdomen and pelvis from progressing to established peritoneal metastases. In some clinical situations with appendiceal and colorectal cancers, the clinical or histopathologic features may indicate that second-look surgery plus perioperative chemotherapy should occur. Peritoneal metastases should always be considered by the multidisciplinary team for treatment or prevention.

Entities:  

Keywords:  Appendiceal cancer; Cancer prevention; Colon cancer; Gastric cancer; Malignant peritoneal mesothelioma; Peritoneal metastases; Recurrent ovarian cancer

Year:  2019        PMID: 30948866      PMCID: PMC6414583          DOI: 10.1007/s13193-018-0856-1

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  102 in total

1.  Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma.

Authors:  S Fujimoto; M Takahashi; T Mutou; K Kobayashi; T Toyosawa
Journal:  Cancer       Date:  1999-02-01       Impact factor: 6.860

2.  Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study.

Authors:  B Sadeghi; C Arvieux; O Glehen; A C Beaujard; M Rivoire; J Baulieux; E Fontaumard; A Brachet; J L Caillot; J L Faure; J Porcheron; J L Peix; Y François; J Vignal; F N Gilly
Journal:  Cancer       Date:  2000-01-15       Impact factor: 6.860

3.  Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution.

Authors:  D Elias; M Bonnay; J M Puizillou; S Antoun; S Demirdjian; Otmany A El; J P Pignon; L Drouard-Troalen; J F Ouellet; M Ducreux
Journal:  Ann Oncol       Date:  2002-02       Impact factor: 32.976

Review 4.  Successful management of microscopic residual disease in large bowel cancer.

Authors:  P H Sugarbaker
Journal:  Cancer Chemother Pharmacol       Date:  1999       Impact factor: 3.333

5.  Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs. delayed management.

Authors:  S R Pestieau; P H Sugarbaker
Journal:  Dis Colon Rectum       Date:  2000-10       Impact factor: 4.585

6.  Quantitative methodologies for selection of patients with recurrent abdominopelvic sarcoma for treatment.

Authors:  B Berthet; T A Sugarbaker; D Chang; P H Sugarbaker
Journal:  Eur J Cancer       Date:  1999-03       Impact factor: 9.162

7.  Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: results of a prospective randomized trial.

Authors:  W Yu; I Whang; H Y Chung; A Averbach; P H Sugarbaker
Journal:  World J Surg       Date:  2001-08       Impact factor: 3.352

8.  Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomized controlled study.

Authors:  Y Yonemura; X de Aretxabala; T Fujimura; S Fushida; K Katayama; E Bandou; K Sugiyama; T Kawamura; K Kinoshita; Y Endou; T Sasaki
Journal:  Hepatogastroenterology       Date:  2001 Nov-Dec

Review 9.  For the clinical application of thermochemotherapy given at mild temperatures.

Authors:  M Urano; M Kuroda; Y Nishimura
Journal:  Int J Hyperthermia       Date:  1999 Mar-Apr       Impact factor: 3.914

Review 10.  Malignant transformation of "benign" cystic mesothelioma of the peritoneum.

Authors:  Santiago González-Moreno; Hui Yan; Kirsten W Alcorn; Paul H Sugarbaker
Journal:  J Surg Oncol       Date:  2002-04       Impact factor: 3.454

View more
  5 in total

Review 1.  Spheroid Formation and Peritoneal Metastasis in Ovarian Cancer: The Role of Stromal and Immune Components.

Authors:  Militsa Rakina; Anna Kazakova; Alisa Villert; Larisa Kolomiets; Irina Larionova
Journal:  Int J Mol Sci       Date:  2022-06-01       Impact factor: 6.208

2.  Selected Patients With Peritoneal Metastases From Breast Cancer May Benefit From Cytoreductive Surgery: The Results of a Multicenter Survey.

Authors:  Maurizio Cardi; Marc Pocard; Rea Lo Dico; Gianmaria Fiorentini; Mario Valle; Roberta Gelmini; Marco Vaira; Enrico Maria Pasqual; Salvatore Asero; Gianluca Baiocchi; Andrea Di Giorgio; Alessandra Spagnoli; Francesco Di Marzo; Bianca Sollazzo; Giuseppe D'Ermo; Daniele Biacchi; Franco Iafrate; Paolo Sammartino
Journal:  Front Oncol       Date:  2022-05-11       Impact factor: 5.738

Review 3.  Surgical treatment of intraperitoneal metastases from lung cancer: two case reports and a review of the literature.

Authors:  Simone Sibio; Giuseppe Sigismondo Sica; Sara Di Carlo; Maurizio Cardi; Alessandra Di Giorgio; Bianca Maria Sollazzo; Paolo Sammartino
Journal:  J Med Case Rep       Date:  2019-08-21

4.  Peritoneal metastasis of colorectal cancer (pmCRC): identification of predictive molecular signatures by a novel preclinical platform of matching pmCRC PDX/PD3D models.

Authors:  Mathias Dahlmann; Guido Gambara; Bernadette Brzezicha; Ulrich Keilholz; Wolfgang Walther; Christian Regenbrecht; Beate Rau; Ulrike Stein; Oliver Popp; Eva Pachmayr; Lena Wedeken; Alina Pflaume; Margarita Mokritzkij; Safak Gül-Klein; Andreas Brandl; Caroline Schweiger-Eisbacher; Philipp Mertins; Jens Hoffmann
Journal:  Mol Cancer       Date:  2021-10-21       Impact factor: 27.401

5.  Preface of the Special Issue: "Peritoneal Surface Malignancies (PSM): The SICO (Italian Society of Surgical Oncology) PSM-Oncoteam Experience, Result Analysis, and Studies' Purpose".

Authors:  Paolo Sammartino; Marco Vaira
Journal:  Cancers (Basel)       Date:  2021-12-20       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.